Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00236444
Other study ID # CR002020
Secondary ID
Status Completed
Phase Phase 3
First received October 7, 2005
Last updated June 6, 2011
Start date December 2001
Est. completion date September 2003

Study information

Verified date November 2010
Source Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of risperidone as maintenance therapy to prevent symptoms of relapse in children and adolescents with conduct and other disruptive behavior disorders, who initially responded well to treatment.


Description:

This is a randomized, double-blind study to compare an oral formulation of risperidone with placebo when taken daily over 24 weeks by children and adolescents with conduct and other disruptive behavior disorders. Patients who do not respond to treatment after an initial 6-week open-label phase, or do not show continued response after 12 weeks, must leave the trial and will not enter into the 24-week double-blind phase. The principal measure of efficacy is the time to symptom relapse. Relapse is assessed by changes in following measures: the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (N-CBRF), a measure of symptoms of conduct and other disruptive behavior disorders and Clinical Global Impression-Severity of Illness (CGI-Severity), and a measure of overall severity of illness. Efficacy assessment also includes Clinical Global Impression-Change (CGI-C), an assessment of improvement, and Visual Analogue Scale for the most troublesome symptom (VAS-MS), which is a scale ranging from not troublesome to extremely troublesome, and Children's Global Assessment Scale (C-GAS), which is an assessment of overall functioning. Safety evaluations include incidence of adverse events, physical examinations, laboratory tests (biochemistry, hematology, and urinalysis), and electrocardiograms (ECGs). The study hypothesis is that daily treatment with an oral formulation of risperidone, compared with placebo, will result in a clinically significant difference in time to relapse, and is well tolerated by children and adolescents with conduct and other disruptive behavior disorders. Oral risperidone solution (1milligram[mg]/milliliter [ml]), daily for 36 weeks. Patients weighing at least 50 kilograms start at 0.5 ml/day and may increase up to.1.5 ml/day. Patients under 50kg start at 0.25ml/day and may increase to 0.75ml/day (maximum).


Recruitment information / eligibility

Status Completed
Enrollment 375
Est. completion date September 2003
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 17 Years
Eligibility Inclusion Criteria:

- Patients must meet criteria of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DMS IV) for Conduct Disorder, Oppositional Defiant Disorder, or Disruptive Behavior Disorder Not Otherwise Specified

- Have a score >=24 on the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (N-CBRF)

- Have no other significant and untreated or unstable medical illness such as diabetes or hypertension, no serious illness of the liver, kidney, or significant disturbances of the cardiac, pulmonary, gastrointestinal, endocrine, or neurological system.

Exclusion Criteria:

- Patients who meet the DSM-IV criteria for: Pervasive Developmental Disorder

- schizophrenia or other psychotic disorders

- Tourette's Disorder

- Generalized Anxiety Disorder

- Major Depression

- Moderate or severe mental retardation

- Substance Dependence

- Patients with a history of neuroleptic malignant syndrome, a rare psychotropic-drug reaction, which may be characterized by confusion, reduced consciousness, high fever or pronounced muscle stiffness

- Hypersensitivity or intolerance to risperidone

- Pregnant or nursing females, or those lacking adequate contraception

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Attention Deficit and Disruptive Behavior Disorders
  • Attention Deficit Disorder with Hyperactivity
  • Mental Disorders

Intervention

Drug:
risperidone


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Outcome

Type Measure Description Time frame Safety issue
Primary Time from start of double-blind phase to relapse, using N-CBRF and CGI assessments.
Secondary Comparison of ratings for risperidone and placebo on N-CBRF, CGI, and VAS-MS throughout study. Ratings on C-GAS once during each study phase. Comparison of safety profiles of risperidone and placebo (for example, adverse events, clinical and lab tests).
See also
  Status Clinical Trial Phase
Completed NCT00600470 - Effectiveness of Collaborative Services in Primary Care for Treating Children With Behavior Disorders Phase 1/Phase 2
Completed NCT03698240 - Mindfulness-based Program for Children With Disruptive Behavior Disorder N/A
Completed NCT02766101 - Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges N/A
Completed NCT02897570 - Metabolic and Neurofunctional Responses to Breakfasts N/A
Recruiting NCT04946253 - SKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care N/A
Completed NCT00402857 - Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders Phase 3
Completed NCT03597789 - Tantrum Tamers 2.0: The Role of Emotion N/A
Recruiting NCT01350986 - Guided Self-Help for Parents of Children With Externalizing Problem Behavior N/A
Completed NCT00163865 - A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents N/A
Completed NCT02893852 - Effects of CO-OP Approach on Activity and Participation of Brazilian Children With Developmental Coordination Disorder N/A
Completed NCT01940978 - A Study of Combination Therapy in Children With ADHD Phase 4
Terminated NCT02094612 - Effectiveness of the Quotient® ADHD Assessment in a System of Care N/A
Completed NCT02305134 - Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial Phase 1/Phase 2
Completed NCT03927612 - Virtual Reality to Improve Social Perspective Taking N/A
Completed NCT03976570 - The Effect of Occupational Therapy on Subthreshold Attention Deficit Hyperactivity Disorder N/A
Recruiting NCT04238403 - Peer Professionals to Increase Capacity to Treat ADHD N/A
Completed NCT00218114 - Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults Phase 3
Completed NCT01919073 - Efficacy of a Brief Behavioral Intervention to Treat ADHD and Disruptive Behaviors In Preschoolers N/A
Completed NCT00001233 - Study of Children at Risk for Disruptive Behavior Disorders N/A
Recruiting NCT05683756 - A Sleep Focused Parenting Intervention for Preschool Aged Children at Risk for ADHD N/A